Upfront

Braun Launches Drug Eluting Balloon Technology

B Braun, a comprehensive solution provider specialising in therapeutic segments of healthcare, launched its path-breaking product 'SeQuent lease' in Kochi.

'SeQuent Please' is an original polymer less drug eluting balloon technology for treating patients suffering from coronary artery diseases. Being polymer less, it has no risk of inflammatory reactions or late stent thrombosis. It provides uniform drug delivery at the target site for faster healing andrespects normal contours of the vessel without stent.

According to Dr Martin Unverdorben, Associate Professor of Medicine, "The polymer less factor of 'SeQuent Please' benefits the patient with fewer side effects. Also, it reduces the need of administering clopidogrel which is an oral anti platelet agent to inhibit blood clots in coronary artery disease. As a result the technology becomes cost effective for the patient."

On the occasion, Dr Upendra Kaul, Executive Director - Academics, Escorts Heart Institute And Research Centre said, "Indian population shows a genetic disposition to cardiac blockages due to plaque formation. Approximately 1,50,000 coronary artery disease patients are intervened by cardiologists, out of which approximately 25-30 per cent show instent restenosis specially in small vessel disease, bifurcation lesions and diabetics.

According to Aditya Banerjee, Dy Country Head, Aesculap Division, B Braun (I) Pvt Ltd, "The research team of B Braun has successfully developed 'SeQuent Please', drug eluting balloon technology, specially designed keeping in mind the unaddressed needs and issues of cardiac restenosis. The product will be commercially available in the Indian market for the benefit of the patients."

EH News Bureau